The utility of copeptin in the emergency department as a predictor of adverse outcomes in non-ST-elevation acute coronary syndrome: the COPED-PAO study

scientific article published on 31 January 2013

The utility of copeptin in the emergency department as a predictor of adverse outcomes in non-ST-elevation acute coronary syndrome: the COPED-PAO study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1136/EMERMED-2012-201996
P698PubMed publication ID23371977

P50authorJuan Gonzalez-CastilloQ74128234
Francisco Javier Martín-SánchezQ82145877
P2093author name stringPablo Herrero
Òscar Miró
Pere Llorens
Pascual Piñera
Miquel Sánchez
COPEP study investigators
P2860cites workPrediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)Q22242088
The TIMI Risk Score for Unstable Angina/Non–ST Elevation MIQ22252998
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromesQ28306261
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.Q33691730
Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial.Q33932812
C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) studyQ34003454
Incremental value of copeptin for rapid rule out of acute myocardial infarctionQ34018239
Copeptin improves early diagnosis of acute myocardial infarctionQ34113939
New biochemical markers in acute coronary syndromesQ37184921
Novel biomarkers in cardiovascular disease: update 2010.Q37799113
The long-term prognostic value of multiple biomarkers following a myocardial infarction.Q40106701
C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarctionQ43795750
Multiple marker approach to risk stratification in patients with stable coronary artery diseaseQ45573743
C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL studyQ46061278
Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patientsQ46515718
ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines).Q55036134
???Q22242895
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectacute coronary syndromeQ266018
P304page(s)286-291
P577publication date2013-01-31
P1433published inEmergency Medicine JournalQ5370622
P1476titleThe utility of copeptin in the emergency department as a predictor of adverse outcomes in non-ST-elevation acute coronary syndrome: the COPED-PAO study
P478volume31

Reverse relations

cites work (P2860)
Q58583594Association between Serum Copeptin and Stroke in Rural Areas of Northern China: A Matched Case-Control Study
Q35556651Copeptin testing in acute myocardial infarction: ready for routine use?
Q57101391Diagnostic accuracy of adding copeptin to cardiac troponin for non-ST-elevation myocardial infarction: A systematic review and meta-analysis
Q38253152The prognostic value of copeptin in patients with acute chest pain

Search more.